Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease
β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition accelerates gray matter atrophy at early stages of the disease even before objective cognitive impairment is manifested. Identification of at-risk individuals at the presymptomatic stage has become a major research...
Saved in:
Published in | JAMA neurology Vol. 70; no. 7; p. 903 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.07.2013
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition accelerates gray matter atrophy at early stages of the disease even before objective cognitive impairment is manifested. Identification of at-risk individuals at the presymptomatic stage has become a major research interest because it will allow early therapeutic interventions before irreversible synaptic and neuronal loss occur. We aimed to further characterize the cross-sectional and longitudinal relationship between Aβ deposition, gray matter atrophy, and cognitive impairment.
To investigate the topographical relationship of Aβ deposition, gray matter atrophy, and memory impairment in asymptomatic individuals with Alzheimer disease pathology as assessed by Pittsburgh compound B positron emission tomography (PiB-PET).
Regional analysis was performed on the cortical surface to relate cortical thickness to PiB retention and episodic memory.
The Australian Imaging, Biomarkers, and Lifestyle Study of Aging, Austin Hospital, Melbourne, Australia.
Ninety-three healthy elderly control subjects (NCs) and 40 patients with Alzheimer disease from the Australian Imaging, Biomarkers, and Lifestyle Study of Aging cohort.
Participants underwent neuropsychological evaluation as well as magnetic resonance imaging and PiB-PET scans. Fifty-four NCs underwent repeated scans and neuropsychological evaluation 18 and 36 months later.
Correlations between cortical thickness, PiB retention, and episodic memory. RESULTS There was a significant reduction in cortical thickness in the precuneus and hippocampus associated with episodic memory impairment in the NC PiB-positive (NC+) group when compared with the NC- group. Cortical thickness was also correlated negatively with neocortical PiB in the NC+ group. Longitudinal analysis showed a faster rate of gray matter (GM) atrophy in the temporal lobe and the hippocampi of the NC+ group. Over time, GM atrophy became more extensive in the NC+ group, especially in the temporal lobe.
In asymptomatic individuals, Aβ deposition is associated with GM atrophy and memory impairment. The earliest signs of GM atrophy were detected in the hippocampus and the posterior cingulate and precuneus regions, and with disease progression, atrophy became more extensive in the temporal lobes. These findings support the notion that Aβ deposition is not a benign process and that interventions with anti-Aβ therapy at these early stages have a higher chance to be effective. |
---|---|
AbstractList | β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition accelerates gray matter atrophy at early stages of the disease even before objective cognitive impairment is manifested. Identification of at-risk individuals at the presymptomatic stage has become a major research interest because it will allow early therapeutic interventions before irreversible synaptic and neuronal loss occur. We aimed to further characterize the cross-sectional and longitudinal relationship between Aβ deposition, gray matter atrophy, and cognitive impairment.
To investigate the topographical relationship of Aβ deposition, gray matter atrophy, and memory impairment in asymptomatic individuals with Alzheimer disease pathology as assessed by Pittsburgh compound B positron emission tomography (PiB-PET).
Regional analysis was performed on the cortical surface to relate cortical thickness to PiB retention and episodic memory.
The Australian Imaging, Biomarkers, and Lifestyle Study of Aging, Austin Hospital, Melbourne, Australia.
Ninety-three healthy elderly control subjects (NCs) and 40 patients with Alzheimer disease from the Australian Imaging, Biomarkers, and Lifestyle Study of Aging cohort.
Participants underwent neuropsychological evaluation as well as magnetic resonance imaging and PiB-PET scans. Fifty-four NCs underwent repeated scans and neuropsychological evaluation 18 and 36 months later.
Correlations between cortical thickness, PiB retention, and episodic memory. RESULTS There was a significant reduction in cortical thickness in the precuneus and hippocampus associated with episodic memory impairment in the NC PiB-positive (NC+) group when compared with the NC- group. Cortical thickness was also correlated negatively with neocortical PiB in the NC+ group. Longitudinal analysis showed a faster rate of gray matter (GM) atrophy in the temporal lobe and the hippocampi of the NC+ group. Over time, GM atrophy became more extensive in the NC+ group, especially in the temporal lobe.
In asymptomatic individuals, Aβ deposition is associated with GM atrophy and memory impairment. The earliest signs of GM atrophy were detected in the hippocampus and the posterior cingulate and precuneus regions, and with disease progression, atrophy became more extensive in the temporal lobes. These findings support the notion that Aβ deposition is not a benign process and that interventions with anti-Aβ therapy at these early stages have a higher chance to be effective. |
Author | Doré, Vincent Bourgeat, Pierrick Acosta, Oscar Masters, Colin L Fripp, Jurgen Chetélat, Gael Martins, Ralph Rowe, Christopher C Zhou, Luping Ames, David Salvado, Oliver Ellis, Kathryn A Villemagne, Victor L |
Author_xml | – sequence: 1 givenname: Vincent surname: Doré fullname: Doré, Vincent email: vincent.dore@csiro.au organization: CSIRO Preventative Health National Research Flagship ICTC, the Australian e-Health Research Centre-BioMedical, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. vincent.dore@csiro.au – sequence: 2 givenname: Victor L surname: Villemagne fullname: Villemagne, Victor L – sequence: 3 givenname: Pierrick surname: Bourgeat fullname: Bourgeat, Pierrick – sequence: 4 givenname: Jurgen surname: Fripp fullname: Fripp, Jurgen – sequence: 5 givenname: Oscar surname: Acosta fullname: Acosta, Oscar – sequence: 6 givenname: Gael surname: Chetélat fullname: Chetélat, Gael – sequence: 7 givenname: Luping surname: Zhou fullname: Zhou, Luping – sequence: 8 givenname: Ralph surname: Martins fullname: Martins, Ralph – sequence: 9 givenname: Kathryn A surname: Ellis fullname: Ellis, Kathryn A – sequence: 10 givenname: Colin L surname: Masters fullname: Masters, Colin L – sequence: 11 givenname: David surname: Ames fullname: Ames, David – sequence: 12 givenname: Oliver surname: Salvado fullname: Salvado, Oliver – sequence: 13 givenname: Christopher C surname: Rowe fullname: Rowe, Christopher C |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23712469$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kE1OwzAUhC0EoqX0Bgj5AE2xncROl1XFn1SJDawrx35pXBI7spOicCy4B2cibeFtnjTzzSzmCp1bZwGhG0rmlBB6t5O1tNB5V80ZofEgcnaGxozyLOI0FSM0DWFHhssISeLkEo1YLChL-GKMvlfehRAFUK1xVlZYWo0rZ7em7bQ5CbLqgwnYFbgtAXuo5IENpWlwDu0HgMXLny-soXHBHKwZVs63Rg3ptjTq3UIIs2NzDbXzPTZ2ILZ2gPdQ9bizpm6k8aAHR5u90Z2swjEwkMvqswRTg8faBJABrtFFMfgw_fsT9PZw_7p6itYvj8-r5TqSMeNtxGOSaC2yJI_5YkEUFCmPtSC5LBgtBIi0UCpLodCpoooKmUouIWUqBRAiX7AJuj31Nl1eg9403tTS95v_9dgvlx17yQ |
CitedBy_id | crossref_primary_10_1007_s10072_020_04864_x crossref_primary_10_3389_fendo_2019_00217 crossref_primary_10_1007_s00259_021_05191_9 crossref_primary_10_1038_s41598_017_06876_8 crossref_primary_10_1016_j_ebiom_2022_104336 crossref_primary_10_1016_j_tics_2013_08_007 crossref_primary_10_3233_JAD_171145 crossref_primary_10_1016_j_neurobiolaging_2017_09_009 crossref_primary_10_1016_j_neurobiolaging_2019_07_005 crossref_primary_10_3390_molecules200813496 crossref_primary_10_1016_j_trci_2017_09_003 crossref_primary_10_1586_14737175_2015_1023296 crossref_primary_10_1016_j_neurobiolaging_2019_02_018 crossref_primary_10_3389_fnins_2023_1275932 crossref_primary_10_1093_brain_awy044 crossref_primary_10_1016_j_jalz_2017_09_013 crossref_primary_10_1002_dad2_12556 crossref_primary_10_1016_j_neuron_2014_10_038 crossref_primary_10_1002_jmri_26810 crossref_primary_10_1097_MD_0000000000000150 crossref_primary_10_1016_j_nicl_2023_103409 crossref_primary_10_1016_j_nicl_2017_10_034 crossref_primary_10_1080_13854046_2023_2184720 crossref_primary_10_3233_JAD_161173 crossref_primary_10_1016_j_neurobiolaging_2017_10_023 crossref_primary_10_1590_0004_282x_anp_2022_s138 crossref_primary_10_1007_s11065_014_9267_4 crossref_primary_10_1016_j_jalz_2016_02_002 crossref_primary_10_1007_s11682_018_9888_y crossref_primary_10_2139_ssrn_4121648 crossref_primary_10_1002_dad2_12022 crossref_primary_10_2217_bmm_13_98 crossref_primary_10_1002_jnr_24739 crossref_primary_10_1016_j_jamda_2016_06_017 crossref_primary_10_3389_fnana_2014_00019 crossref_primary_10_1016_j_jcmg_2014_09_018 crossref_primary_10_1371_journal_pone_0224030 crossref_primary_10_1038_s41598_019_39809_8 crossref_primary_10_1038_s41598_019_47638_y crossref_primary_10_1016_j_neurobiolaging_2023_05_009 crossref_primary_10_1371_journal_pone_0152983 crossref_primary_10_1016_j_neurobiolaging_2015_06_027 crossref_primary_10_1093_brain_awv326 crossref_primary_10_1097_RLU_0000000000001147 crossref_primary_10_3233_JAD_179928 crossref_primary_10_3389_fnagi_2022_1054516 crossref_primary_10_1017_S1355617716000813 crossref_primary_10_1093_braincomms_fcad192 crossref_primary_10_1007_s11682_013_9278_4 crossref_primary_10_1016_j_dadm_2018_08_007 crossref_primary_10_1007_s12603_014_0507_3 crossref_primary_10_1016_j_jalz_2014_11_002 crossref_primary_10_1016_j_neuroscience_2014_11_063 crossref_primary_10_1038_s41598_024_74262_2 crossref_primary_10_1016_j_trci_2018_04_007 crossref_primary_10_1016_j_jalz_2016_06_2365 crossref_primary_10_3233_JAD_230030 crossref_primary_10_3233_JAD_231362 crossref_primary_10_1002_alz_13083 crossref_primary_10_1093_brain_aww200 crossref_primary_10_3389_fnagi_2018_00325 crossref_primary_10_1016_j_neuint_2022_105401 crossref_primary_10_3233_JAD_170720 crossref_primary_10_1002_hbm_26532 crossref_primary_10_3389_fnimg_2022_828767 crossref_primary_10_3233_JAD_170448 crossref_primary_10_1002_brb3_1601 crossref_primary_10_1007_s12603_014_0485_5 crossref_primary_10_1016_j_arr_2016_01_002 crossref_primary_10_1093_gerona_glad114 crossref_primary_10_1142_S0129065716500039 crossref_primary_10_3233_JAD_220249 crossref_primary_10_1007_s11682_021_00558_w crossref_primary_10_3233_ADR_210005 crossref_primary_10_1016_j_bbr_2021_113387 crossref_primary_10_1038_nrneurol_2018_9 crossref_primary_10_1093_arclin_acu068 crossref_primary_10_1093_braincomms_fcae451 crossref_primary_10_1016_j_neurobiolaging_2018_01_017 crossref_primary_10_7554_eLife_77745 crossref_primary_10_1007_s10072_018_3620_y crossref_primary_10_2967_jnmt_123_265568 crossref_primary_10_1177_13872877251316801 crossref_primary_10_3390_brainsci13040631 crossref_primary_10_1186_s12877_020_1423_5 crossref_primary_10_1093_cercor_bhx099 crossref_primary_10_1186_s13195_014_0062_5 crossref_primary_10_3389_fnagi_2024_1356656 crossref_primary_10_1007_s40263_019_00613_7 crossref_primary_10_1002_brb3_2837 crossref_primary_10_1016_j_dadm_2015_11_003 crossref_primary_10_1097_MNM_0000000000001042 crossref_primary_10_1016_j_nicl_2018_04_016 crossref_primary_10_3233_JAD_160327 crossref_primary_10_3233_JAD_170261 crossref_primary_10_1007_s00429_019_01915_8 crossref_primary_10_3233_JAD_150877 crossref_primary_10_1016_j_jalz_2016_08_010 crossref_primary_10_1590_1980_57642021dn15_030002 crossref_primary_10_1016_j_neurobiolaging_2016_06_003 crossref_primary_10_1038_s41583_018_0067_3 crossref_primary_10_1038_s41598_018_20513_y crossref_primary_10_1002_acn3_51273 crossref_primary_10_1007_s00259_019_04446_w crossref_primary_10_1111_joa_12155 crossref_primary_10_1016_j_jpsychires_2017_02_019 crossref_primary_10_1016_j_jalz_2014_04_513 crossref_primary_10_1007_s13346_021_00940_7 crossref_primary_10_3233_JAD_201133 crossref_primary_10_1002_hbm_23719 crossref_primary_10_1016_j_nicl_2016_06_010 crossref_primary_10_1016_j_nicl_2017_01_026 crossref_primary_10_12779_dnd_2019_18_4_113 crossref_primary_10_1016_j_neurobiolaging_2018_11_005 crossref_primary_10_1007_s00259_014_2704_z crossref_primary_10_1016_j_dadm_2015_01_003 crossref_primary_10_3389_fonc_2020_573512 crossref_primary_10_1016_j_yebeh_2020_107278 crossref_primary_10_1002_alz_14415 crossref_primary_10_3233_ADR_230027 crossref_primary_10_1002_hbm_24799 crossref_primary_10_1016_j_jalz_2015_03_002 crossref_primary_10_1053_j_semnuclmed_2016_09_006 crossref_primary_10_1159_000526297 crossref_primary_10_1038_s41598_017_09577_4 crossref_primary_10_1002_mds_26590 crossref_primary_10_1111_ene_15241 crossref_primary_10_1002_dad2_12291 crossref_primary_10_1038_s41598_018_21983_w crossref_primary_10_1093_brain_aww193 crossref_primary_10_3389_fneur_2020_00053 crossref_primary_10_1002_alz_13576 crossref_primary_10_1016_j_jhazmat_2024_134756 crossref_primary_10_1016_j_cnp_2018_06_001 crossref_primary_10_3390_jimaging8040103 crossref_primary_10_1002_sim_8568 crossref_primary_10_1080_23279095_2019_1710509 crossref_primary_10_1002_dad2_12288 crossref_primary_10_61186_nl_3_3_19 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1001/jamaneurol.2013.1062 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2168-6157 |
ExternalDocumentID | 23712469 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | 0R~ 4.4 53G AAGZG ABIVO ABJNI ACDNT ACGFS ACPRK ADBBV ADHGD AENEX AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EJD EMOBN EX3 H13 NPM OB2 OBH OHH OVD PQQKQ RAJ SV3 TEORI WOW |
ID | FETCH-LOGICAL-a326t-6304dd784b36990cef563d70baf21f7e75fcc85efd5c1c17a5a6ae52c5ee77b92 |
IngestDate | Thu Apr 03 07:00:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a326t-6304dd784b36990cef563d70baf21f7e75fcc85efd5c1c17a5a6ae52c5ee77b92 |
PMID | 23712469 |
ParticipantIDs | pubmed_primary_23712469 |
PublicationCentury | 2000 |
PublicationDate | 2013-07-01 |
PublicationDateYYYYMMDD | 2013-07-01 |
PublicationDate_xml | – month: 07 year: 2013 text: 2013-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JAMA neurology |
PublicationTitleAlternate | JAMA Neurol |
PublicationYear | 2013 |
SSID | ssj0000800434 |
Score | 2.4893458 |
Snippet | β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition accelerates gray matter atrophy at early stages of the disease even... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 903 |
SubjectTerms | Aged Aged, 80 and over Aging - metabolism Aging - pathology Aging - physiology Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer Disease - physiopathology Amyloid beta-Peptides - metabolism Atrophy Cerebral Cortex - metabolism Cerebral Cortex - pathology Cerebral Cortex - physiopathology Cross-Sectional Studies Female Humans Longitudinal Studies Magnetic Resonance Imaging - instrumentation Magnetic Resonance Imaging - methods Male Memory Disorders - metabolism Memory Disorders - pathology Memory Disorders - physiopathology Memory, Episodic Positron-Emission Tomography Prodromal Symptoms |
Title | Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23712469 |
Volume | 70 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELa6ICEuiH9YfuQDe-oGNbYTu8du2dUKaTntor2tHMeBQJtU2vbAPtbyHrwGr8GM7SRW-RFwiSq7jZrMp_GM_X0zhLzS3CgFCU7CuGAJrNcmUSU4QylLLSCTs8qVFDp5lx-fibfn2flo9D1iLW3WxWtz9Utdyf9YFcbArqiS_QfL9jeFAfgM9oUrWBiuf2XjOS5xyaVjUzVB9L9osQPRpqz9wFByxHEJO-pbTNGa7c0P9w4YkmIDgwvfO2SlfpsbCfGf0SF2RM8lknOdXLDnHi2-jDcNCi5rpLPXvcjrMhR3Gs8WVx9tvcR25NGJUBcUg-Mfu8Ka8Rb_mzac4jsqbt2YiKLzHhWMS_0h8HRrPHkY99vYBy1qvbXnH9dYetL0eqQjcJIrL0dB2Wm86YENKGS36WGdc2RpriDt9cWtO0_uW5AExMrILU9dHYWfl4uhTYF_SKT6cRj2C0SEoNXSQYhxCfGQ7y3z59mtIt7d1A7ZgXQG-7OGTaVPIWgXXPTCTl8Ta_sfYdnqcJetFMiFQqd3yZ2Qw9CZB-Q9MrLNfXLrJLA0HpCvW7ikAAIa45J2uKRtRQGXNMYlDbiks2_XdMDkPu0QSXtE7rs7ezzSuqERHumARxrh0f0AvtnjkQY8PiRnR4en8-MkNAdJNGQc6yTnE1GWUomC5xBRGVtlOS_lpNAVSytpZVYZozJblZlJTSp1pnNtM2Yya6UspuwRudG0jX1C6EQZLrgtuFaVUDkv9BTi2FSkdmrSyrKn5LF_3RcrXwHmojPE7m9nnpHbA26fk5sVPKJ9AfHrunjprP8DUDGmFA |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-sectional+and+longitudinal+analysis+of+the+relationship+between+A%CE%B2+deposition%2C+cortical+thickness%2C+and+memory+in+cognitively+unimpaired+individuals+and+in+Alzheimer+disease&rft.jtitle=JAMA+neurology&rft.au=Dor%C3%A9%2C+Vincent&rft.au=Villemagne%2C+Victor+L&rft.au=Bourgeat%2C+Pierrick&rft.au=Fripp%2C+Jurgen&rft.date=2013-07-01&rft.eissn=2168-6157&rft.volume=70&rft.issue=7&rft.spage=903&rft_id=info:doi/10.1001%2Fjamaneurol.2013.1062&rft_id=info%3Apmid%2F23712469&rft_id=info%3Apmid%2F23712469&rft.externalDocID=23712469 |